{"id":"hb0017-q8w","safety":{"commonSideEffects":[{"rate":"null","effect":"Pneumonitis"},{"rate":"null","effect":"Hypothyroidism"},{"rate":"null","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, HB0017 Q8W prevents the interaction with its ligands, PD-L1 and PD-L2, thereby releasing the inhibition on T cells and enhancing the immune response against cancer cells.","oneSentence":"HB0017 Q8W is a monoclonal antibody targeting the PD-1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:14:55.527Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Head and neck squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT06592274","phase":"PHASE2","title":"A Phase 2 Study of HB0017 in Psoriasis Patients","status":"RECRUITING","sponsor":"Huabo Biopharm Co., Ltd.","startDate":"2024-09-30","conditions":"Psoriasis (PsO)","enrollment":200},{"nctId":"NCT06477237","phase":"PHASE3","title":"Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis","status":"RECRUITING","sponsor":"Huabo Biopharm Co., Ltd.","startDate":"2024-03-01","conditions":"Psoriasis","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HB0017 Q8W","genericName":"HB0017 Q8W","companyName":"Huabo Biopharm Co., Ltd.","companyId":"huabo-biopharm-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"HB0017 Q8W is being studied in a Phase III clinical trial for the treatment of moderate to severe plaque psoriasis. The study is a multicenter, randomized, double-blind, placebo-controlled trial that also includes HB0017 Q4W as an intervention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}